The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated ...

(UroToday.com) The 2026 ASCO annual meeting featured an optimizing care for patients with metastatic castration resistant prostate cancer (mCRPC) session and a presentation by Dr. Karim Fizazi ...

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% ...

One patient developed transient, low-titer and non-neutralizing anti-PTH antibodies, with no impact on safety or efficacy.

Multi-organ system and quality-of-life benefits sustained through five years of treatment - 82% response rate for the multi-component endpoint - 95% of patients completed five years of treatment COPEN ...